HUBEI LONGXIANG PHARMACEUTICAL TECH.CO.,LTD.
湖北龍翔製薬技術有限公司 - ホームページ
湖北龍翔製薬技術有限公司は2008年1月に設立され、登録資本金は1億2,200万元です。支配株主は天津瑞埔生物技術有限公司（証券コード：300119）です。 Longxiang Pharmaceutical は、2017 年 4 月に新第三板に上場されました (証券コード: 871082)。従業員数は 340 名を超え、総資産は 5 億 6,000 万元です。
- Type
- manufacturer (our classification of the record, not a statement by the company)
- Role
- Manufacturer
- Location
- Wuxue, China
- Website
- https://www.lxpharm.com
- Categories
- 医薬品製造, 化学薬品とプラスチック, 獣医製品と動物の健康
Listed in a source registry
What is established and what is not
No facet of this company has been investigated yet. The facts below are collected records, not an assessment: nothing here confirms manufacturing, ownership or trading status beyond what each record literally says.
Verified facts
- corporate-mail-on-domain (green), checked 2026-08-09 Mail server of the company domain
- domain-registered (green), checked 2026-08-09 Domain registry record
- debarment-clear (green), checked 2026-08-09 - screened by name only: no legal entity is established for this record, so this is not a clearance OpenSanctions
- lei-lapsed (amber), checked 2026-08-09 GLEIF
- sanctions-clear (green), checked 2026-08-09 - screened by name only: no legal entity is established for this record, so this is not a clearance OpenSanctions
Import rules for these goods
- Medicines imported into the EU must come from a site holding an EU GMP certificate, and the importer needs a manufacturing/import authorisation. European Medicines Agency (GMP)